ClinicalTrials.gg
RecruitingNCT05680012Updated Jul 28, 2026

Tissue Destruction and Healing in Celiac Disease

An interventional study of Gluten containing snack bar in Celiac Disease, sponsored by University of Chicago. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by University of Chicago · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Planned enrollment
7th of 68
220 · median 46
Started
2023
with 6 others
No phase
26 of 103
5 open now
Primary completion
2027-05
later than 8 of 19 live
Registered
91st of 103
by date

Among the 103 studies in Celiac Disease with a site in United States, this one is the 7th largest by planned enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2023, is one of 26 with no phase, reaches primary completion later than 8 of the 19 other live ones, and was the 91st registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.

Read the detailed description

Celiac disease is an autoimmune enteropathy characterized by chronic inflammation of the small intestinal mucosa triggered by gluten uptake that occurs in genetically susceptible individuals carrying the specific class II human leucocyte antigens (HLA) DQ2 and DQ8 alleles. There is a spectrum in intestinal tissue damage associated with celiac disease. Some individuals develop inflammatory immunity in the absence of tissue damage, while others experience tissue damage ranging from partial to total villous atrophy. Persistent mucosal damage is associated with several severe complications, including lymphoproliferative malignancy and bone diseases. In addition, individuals with active celiac disease display a wide range of clinical symptoms, including metabolic defects that are not correlated to the degree of villous atrophy. Although much progress has been made in understanding celiac disease, major gaps remain in understanding biological mechanisms underlying inter-individual differences in clinical presentations and capacity to heal while maintaining a gluten-free diet.

03

Conditions studied

  • Celiac Disease

Browse trials for

Keywords

  • gluten-free diet
  • HLA-DQ2
  • HLA-DQ8
  • microbiome
  • metagenomics
  • intestinal epithelial cells
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Gluten challenge group:

  1. Age 18 to 75 years old
  2. Diagnosis of Celiac disease for at least 12 months by intestinal
  3. Follow a strict gluten-free diet for at least the 12 consecutive months

Gluten de-challenge group:

  1. Age 18 to 75 years old
  2. Showing typical celiac disease symptoms
  3. Not on a gluten-free diet

Control group:

  1. Age 18 to 75 years old
  2. Females who are not pregnant

Exclusion criteria

Exclusion Criteria:

Gluten challenge group:

  1. Diagnosis of any severe complication of celiac disease
  2. Diagnosis of other chronic, active GI disease
  3. Selective IgA deficiency
  4. Severe reaction to gluten exposure
  5. Any diseases
  6. History of significant substance or alcohol abuse
  7. Pregnant or lactating
  8. Diagnosis of blood clotting disorders

Gluten de-challenge group:

  1. History of chronic inflammatory gastrointestinal disease
  2. Gastrointestinal illness within the 4-week period prior to screening
  3. History of lymphoproliferative disease
  4. Uncontrolled blood clotting disorders
  5. Any clinically significant diseases
  6. History of significant substance or alcohol abuse

Control group:

  1. Taking antibiotics, proton pump inhibitors, aspirin, or non-steroidal anti-inflammatory drugs
  2. Known intestinal inflammation
  3. Prior gastrointestinal surgery
  4. Taking of antiplatelet agents or anticoagulants
  5. Family history of celiac disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Gluten challenge group

    Diagnosis of celiac disease by intestinal biopsy and serology for at least 12 months

    Dietary Supplement: Gluten containing snack bar

  • No intervention
    Gluten de-challenge group

    Suspected celiac disease either showing typical symptoms or positive celiac disease serology

  • No intervention
    Control group

    No history or symptoms of celiac disease

Interventions

  • Dietary supplementGluten containing snack bar

    Ingest snack bars containing 3 grams of gluten every day for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Gluten challenge group: quantitative analysis of intestinal villus to crypt ratios

    villus to crypt ratios will be quantified on small bowel biopsy samples for the histologic quantification of intestinal responses to disease processes.

    Time frame: baseline - 6 weeks

  2. Gluten de-challenge group: quantitative analysis of intestinal villus to crypt ratios

    Villus to crypt ratios will be quantified on small bowel biopsy samples for the histologic quantification of intestinal responses to disease processes.

    Time frame: baseline -12 months

07

Study locations

2 of 3 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for May 2027, 45 months after the start.

Of 82 non-industry interventional studies with no phase under Celiac Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 45 months is above that.

Counting every sponsor, half of 87 studies reached it within 27 months; a quarter within 12 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Jan 11, 2023
StartActual
Jul 14, 2023
Primary completionEst.
May 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05680012
Responsible party
Sponsor
First posted
Jan 11, 2023
Start date
Jul 14, 2023
Primary completion
May 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jul 28, 2026

Study contacts

Sonia Kupfer, MD
Contact
skupfer@bsd.uchicago.edu
(773) 834-1438
Kristi Kearney, RN
Contact
kkearney@bsd.uchicago.edu
773-834-7414
Bana Jabri, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion